PRGO reported Q1 2026 results today at the most consequential moment in its multi-year restructuring, landing an earnings beat that markets have greeted cautiously — and for good reason.
Adjusted EPS came in at $0.43, well ahead of the $0.31 consensus. Full-year guidance was reaffirmed: adjusted EPS of $2.25–$2.55 against a $2.11 estimate, with sales guided at $4.02B–$4.19B. That guidance reaffirmation matters. Perrigo has spent the past year in what management explicitly calls a "transition year," and investors needed confirmation that the trajectory hasn't slipped. The beat was real — helped by tariff recovery credits, a lower tax rate, and early cost-saving programme benefits. But revenue told a different story. Q1 sales of $939M missed the $1.03B estimate by a notable margin, weighed down by softer cough-and-cold incidence (a roughly 3.5% headwind to core sales), retailer inventory destocking in both the US and Europe, and carryover manufacturing volume headwinds that management pegged at a $0.60 full-year EPS drag. The stock had drifted up 7.3% over the past month to $11.64 ahead of the print, suggesting some optimism was already priced in before the numbers landed.
The positioning data tells a story of shorts quietly retreating. Short interest has fallen roughly 13% over the past month — from around 15.8M shares to 13.5M — leaving SI at 9.8% of free float. That's still meaningfully elevated, but the directional move is clear. Around April 23 there was a sharp single-day drop in shorted shares of nearly 2.2M, representing the biggest one-day unwind in the data window. The lending market has eased alongside that retreat. Cost to borrow, at 0.44%, is the lowest in six weeks and has fallen 15% over the past month. Availability is not tight — the borrow market is loose, with shorts able to exit and re-enter without friction. Options lean call-heavy: the put/call ratio of 0.27 runs above its 20-day average of 0.22, but only modestly so (z-score near 1.0), well off the 52-week high of 0.97. Taken together, positioning looks like a cautious de-risking ahead of the print rather than a conviction short.
The Street entered this week with mixed signals and largely stale targets. JP Morgan's Chris Schott, who cut the rating to Neutral and slashed the target from $32 to $20 back in November 2025, and Canaccord's Susan Anderson, who maintained Buy while halving her target to $20 at the same time, both went quiet after a February round of target trims to $18 and $17 respectively. The most recent analyst data is dated February 2026 — over two months old — and the consensus target of $17 implies roughly 46% upside to the current price of $11.64. That gap is large, but the direction of travel in analyst revisions over the past year has been unambiguously downward: targets have been cut at nearly every turn, with the aggregate target moving from the low $40s in mid-2024 to $17–$18 today. The valuation setup is interesting on paper: P/E near 5.3x and EV/EBITDA at 7.7x are not demanding for a self-care business with a genuine recovery thesis. The dividend score ranks in the 98th percentile — though the last actual dividend paid was in 2022 and should not be read as current income.
The institutional picture shows meaningful buying. Fuller & Thaler built a new position of over 5.8M shares (reported February 2026), making it the fourth-largest holder at 5.7% of shares. BlackRock added 3.1M shares in April, lifting its position to 12.1% of shares outstanding. T. Rowe Price added over 1M shares in Q1. That breadth of institutional accumulation — across quant, active, and passive managers — at these price levels suggests at least a subset of large holders sees the current valuation as a buying opportunity, not just a value trap. The CEO and CFO did execute small sell trades in April following share awards, but the values were trivial (under $100,000), typical of tax-driven withholding sales rather than directional statements.
The February Q4 2025 print provides one genuine reference point. After that release, the stock fell 13% on the day and 24.5% over the following five sessions — the single largest reaction in the recent history available. That print included a $1.4B net loss driven by goodwill impairment charges. The Q1 2026 report is a different situation structurally: no impairment charges were flagged, the EPS beat was wide, and guidance was held. Whether the Street reacts better this time — or treats the revenue miss as confirmation of the bear case around volume recovery timing — will likely define the stock's trajectory into summer.
The call transcript is now available. Management's language around H2 weighting of earnings and cost savings — "benefits from these initiatives are not yet fully realized" — is either the setup for a credible recovery or the familiar deferral of hard news. What to watch: Q2 results and whether retailer destocking in the US and European OTC markets begins to reverse, given that two-thirds of Q1's revenue miss was attributed to that single factor.
See the live data behind this article on ORTEX.
Open PRGO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
